Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States

被引:8
|
作者
Asche, Carl V. [1 ,2 ,3 ]
Zografos, Panagiotis [4 ]
Norlin, Jenny M. [5 ]
Urbanek, Bill [4 ]
Mamay, Carl [4 ,6 ]
Makin, Charles
Erntoft, Sandra [5 ]
Chen, Chi-Chang [6 ]
Hines, Dionne M. [6 ]
Siegel, Daniel Mark [7 ,8 ]
机构
[1] Univ Illinois, Coll Med, Ctr Outcomes Res, One Illini Dr, Peoria, IL 61656 USA
[2] Univ Illinois, Coll Med, Dept Med, Peoria, IL 61656 USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[4] LEO Pharma Inc, Parsippany, NJ USA
[5] LEO Pharma A S, Ballerup, Denmark
[6] IMS Hlth, RWE HEOR Plymouth Meeting, Philadelphia, PA USA
[7] Suny Downstate, Dept Dermatol, Brooklyn, NY USA
[8] Long Isl Skin Canc Dermatol Surg, Smithtown, NY USA
关键词
actinic keratosis; health care resource utilization; treatment patterns; PHOTODYNAMIC THERAPY; FIELD CANCERIZATION; ECONOMIC-EVALUATION; SOLAR KERATOSES; CELL CARCINOMA; POPULATION; RISK; EPIDEMIOLOGY; NETHERLANDS; PREVALENCE;
D O I
10.1016/j.jval.2015.11.014
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To compare health care resource utilization and treatment patterns between patients with actinic keratosis (AK) treated with ingenol mebutate gel (IngMeb) and those treated with other field directed AK therapies. Methods: A retrospective, propensity-score matched, cohort study compared refill/repeat and adding-on/switching patterns and outpatient visits and prescriptions (health care resource utilization) over 6 months in patients receiving IngMeb versus those receiving imiquimod, 5-fluorouracil, diclofenac sodium, and methyl aminolevulinate or aminolevulinic acid photodynamic therapy (MAL/ALA-PDT). Results: The final sample analyzed included four matched treatment cohort pairs (IngMeb and comparator; n = 790-971 per treatment arm). Refill rates were similar except for imiquimod (15% vs. 9% for imiquimod and IngMeb, respectively; P < 0.05). MAL/ALA-PDT treatment repetition rates were higher than IngMeb refill rates (20% vs. 10%; P < 0.05). Topical agent add-on/switch rates were comparable. PDT had higher switch rates than did IngMeb (5% vs. 2%; P < 0.05). The IngMeb cohort had a significantly lower proportion of patients with at least one AK-related outpatient visit during the 6-month follow-up than did any other cohort: versus imiquimod (50% vs. 66%; P < 0.0001), versus 5-fluorouracil (50% vs. 69%; P < 0.0001), versus diclofenac sodium (51% vs. 56%; P = 0.034), and versus MAL/ALA-PDT (50% vs. 100%; P < 0.0001). There were significantly fewer AK-related prescriptions among patients receiving IngMeb than among patients in other cohorts. Conclusions: Results based on the first 6 months after treatment initiation suggested that most field-directed AK therapies had clinically comparable treatment patterns except imiquimod, which was associated with higher refill rates, and PDT, which was associated with significantly more frequent treatment sessions and higher switching rates. IngMeb was also associated with significantly fewer outpatient visits than were other field-directed therapies.
引用
收藏
页码:239 / 248
页数:10
相关论文
共 50 条
  • [41] HEALTH CARE RESOURCE UTILIZATION AND COSTS OF PATIENTS WITH ASPERGILLOSIS IN THE UNITED STATES
    Durden, E.
    Juneau, P.
    Chaudhari, P.
    McMorrow, D.
    Fowler, R.
    Horn, D.
    VALUE IN HEALTH, 2013, 16 (03) : A86 - A86
  • [42] REAL WORLD EVIDENCE ON THE IMPACT OF ELAGOLIX UTILIZATION ON PAIN SYMPTOMS, TREATMENT PATTERNS AND HEALTH RESOURCE USE AMONG ENDOMETRIOSIS PATIENTS IN THE UNITED STATES
    Surrey, E. S.
    Soliman, A. M.
    Johns, B.
    Vora, J.
    Cross, S.
    Agarwal, S. K.
    VALUE IN HEALTH, 2020, 23 : S119 - S119
  • [43] Real World Treatment Patterns, Adverse Events and Healthcare Resource Utilization and Costs Among Chronic Lymphocytic Leukemia (CLL) Patients in the United States
    Kabadi, Shaum
    Le, Lisa
    Byfield, Stacey Dacosta
    Olufade, Temitope O.
    BLOOD, 2018, 132
  • [44] Utilization and Treatment Patterns of Cytoreduction Surgery and Intraperitoneal Chemotherapy in the United States
    Ryan J. Ellis
    Cary Jo R. Schlick
    Anthony D. Yang
    Emma L. Barber
    Karl Y. Bilimoria
    Ryan P. Merkow
    Annals of Surgical Oncology, 2020, 27 : 214 - 221
  • [45] Utilization and Treatment Patterns of Cytoreduction Surgery and Intraperitoneal Chemotherapy in the United States
    Ellis, Ryan J.
    Schlick, Cary Jo R.
    Yang, Anthony D.
    Barber, Emma L.
    Bilimoria, Karl Y.
    Merkow, Ryan P.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (01) : 214 - 221
  • [47] Costs, Resource Utilization, and Treatment Patterns for Patients with Metastatic Melanoma
    Toy, Edmond L.
    Lewis, Michael C.
    Oglesby, Alan K.
    Duh, Mei S.
    Vekeman, Francis
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 478 - 479
  • [48] Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients
    Joe, Hyun Jae
    Oh, Byung Ho
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2017, 10 : 93 - 98
  • [49] A REAL-WORLD ASSESSMENT OF THE TREATMENT PATTERNS, HEALTH RESOURCE UTILIZATION AND OUTCOMES ASSOCIATED WITH ESOPHAGEAL CANCER IN THE UNITED STATES
    Hauser, R.
    Huff, K.
    Friedman, H. S.
    Navaratnam, P.
    Xiao, H.
    Gricar, J.
    VALUE IN HEALTH, 2021, 24 : S20 - S20
  • [50] Real-world treatment and resource utilization for menopausal symptoms in the United States
    DePree, Barbara
    Houghton, Katherine
    Shiozawa, Aki
    Esterberg, Elizabeth
    King, Deanna
    Kim, Janet
    Mancuso, Shayna
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2021, 28 (12): : 1447 - 1447